These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27993966)

  • 1. Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.
    Lam HM; McMullin R; Nguyen HM; Coleman I; Gormley M; Gulati R; Brown LG; Holt SK; Li W; Ricci DS; Verstraeten K; Thomas S; Mostaghel EA; Nelson PS; Vessella RL; Corey E
    Clin Cancer Res; 2017 May; 23(9):2301-2312. PubMed ID: 27993966
    [No Abstract]   [Full Text] [Related]  

  • 2. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Puhr M; Eigentler A; Handle F; Hackl H; Ploner C; Heidegger I; Schaefer G; Brandt MP; Hoefer J; Van der Pluijm G; Klocker H
    Oncogene; 2021 Apr; 40(17):3087-3100. PubMed ID: 33795839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
    Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
    [No Abstract]   [Full Text] [Related]  

  • 6. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
    Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
    Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.
    Boukovala M; Spetsieris N; Weldon JA; Tsikkinis A; Hoang A; Aparicio A; Tu SM; Araujo JC; Zurita AJ; Corn PG; Pagliaro L; Kim J; Wang J; Subudhi SK; Tannir NM; Logothetis CJ; Troncoso P; Wen S; Efstathiou E
    Eur J Cancer; 2020 Mar; 127():67-75. PubMed ID: 31986451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
    Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
    Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.
    Sowalsky AG; Ye H; Bhasin M; Van Allen EM; Loda M; Lis RT; Montaser-Kouhsari L; Calagua C; Ma F; Russo JW; Schaefer RJ; Voznesensky OS; Zhang Z; Bubley GJ; Montgomery B; Mostaghel EA; Nelson PS; Taplin ME; Balk SP
    Cancer Res; 2018 Aug; 78(16):4716-4730. PubMed ID: 29921690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
    Toren PJ; Kim S; Pham S; Mangalji A; Adomat H; Guns ES; Zoubeidi A; Moore W; Gleave ME
    Mol Cancer Ther; 2015 Jan; 14(1):59-69. PubMed ID: 25351916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
    Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
    Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
    Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
    Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.
    Cao S; Ma T; Ungerleider N; Roberts C; Kobelski M; Jin L; Concha M; Wang X; Baddoo M; Nguyen HM; Corey E; Fazli L; Ledet E; Zhang R; Silberstein JL; Zhang W; Zhang K; Sartor O; Dong X; Flemington EK; Dong Y
    Oncogene; 2019 Nov; 38(45):7060-7072. PubMed ID: 31409897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
    Nouri M; Massah S; Caradec J; Lubik AA; Li N; Truong S; Lee AR; Fazli L; Ramnarine VR; Lovnicki JM; Moore J; Wang M; Foo J; Gleave ME; Hollier BG; Nelson C; Collins C; Dong X; Buttyan R
    Clin Cancer Res; 2020 Apr; 26(7):1678-1689. PubMed ID: 31919137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.
    Rotinen M; You S; Yang J; Coetzee SG; Reis-Sobreiro M; Huang WC; Huang F; Pan X; Yáñez A; Hazelett DJ; Chu CY; Steadman K; Morrissey CM; Nelson PS; Corey E; Chung LWK; Freedland SJ; Di Vizio D; Garraway IP; Murali R; Knudsen BS; Freeman MR
    Nat Med; 2018 Dec; 24(12):1887-1898. PubMed ID: 30478421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.